Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations

NCT06715124 is registered in ClinicalTrials.gov with Quanta Therapeutics as lead sponsor.

NCT NCT06715124
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06715124 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Trial Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations
Lead sponsor
Quanta Therapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
January 14, 2025
Completion date
January 2, 2029
Enrollment
237 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors